Cyclopharm Limited (CYC) AI Stock Analysis

• Market Cap: AU$106.69M
• Dividend Yield: N/A
• Average Volume (3M): 97.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 34.20%
• EPS Growth: -23.90%
• Country: AU
• Employees: 95
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 111,136,850
• 10 Day Avg. Volume: 155,345
• 30 Day Avg. Volume: 97,642
• PEG Ratio: -0.08
• Price to Book (P/B): 3.83
• Price to Sales (P/S): 5.93
• P/FCF Ratio: -12.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: AU$1.00 ▲(2.04% Upside)

The score is held down primarily by weak financial performance, with ongoing losses and negative operating/free cash flow despite a solid balance-sheet leverage profile. Technicals provide partial support due to an established uptrend, but momentum indicators are near overbought levels. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.

Positive Factors

Recurring consumable revenue

Cyclopharm's core revenue is recurring consumable sales tied to each patient study. This creates a predictable, usage-driven revenue stream that scales with procedure volumes and the installed base, supporting durable top-line cash inflows as clinical adoption persists.

Installed base driving future demand

Equipment sales expand the installed base of Technegas generators, creating long-term follow-on consumable demand and service opportunities. A growing installed base makes revenue more durable and helps lock customers into the Technegas ecosystem over multiple years.

Low financial leverage

Cyclopharm's low leverage and high equity ratio provide financial flexibility to withstand near-term earnings pressures, fund strategic initiatives, and invest in commercial expansion without heavy debt servicing, supporting stability over the medium term.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow reduces internal funding for R&D, marketing and service expansion. Over months, this constrains reinvestment, increases reliance on external financing, and limits the firm's ability to scale its installed base organically.

Persistent net losses and negative EBIT

Ongoing losses and negative EBIT indicate the business has not yet translated revenue growth into profitability. Without margin improvement, persistent deficits will pressure reserves and could force cost cuts or dilute shareholders to sustain operations.

Operational efficiency challenges

Despite modest revenue growth, the lack of positive net income highlights inefficiencies in cost structure or pricing. Over 2-6 months, failure to improve margins limits free cash flow conversion and weakens the economics of scaling the consumable/equipment model.

Cyclopharm Limited Business Overview & Revenue Model

Company Description

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

How the Company Makes Money

Cyclopharm generates revenue primarily through the sale of its radiopharmaceutical products, particularly Technegas, which is utilized in various diagnostic imaging procedures. The company also earns money through licensing agreements and partnerships with healthcare institutions and distributors who facilitate the delivery of its products to hospitals and clinics. Additionally, Cyclopharm may benefit from collaborations with research institutions and pharmaceutical companies that seek to utilize its technology for clinical trials or new product development. Grant funding and government support for research and development activities also contribute to the company's earnings.

Cyclopharm Limited Financial Statement Overview

Summary

Revenue has grown modestly, and leverage is low (Debt-to-Equity 0.19; equity ratio 68.8%), but the company continues to post negative EBIT and net income with negative operating and free cash flow, indicating weak profitability and cash generation.

Income Statement

Cyclopharm Limited has shown consistent growth in revenue over the years, with a revenue growth rate of 1.6% from 2023 to 2024. However, the company is struggling with profitability, evidenced by persistent negative EBIT and net income, resulting in negative profit margins. Despite some growth in gross profit, the absence of positive net income and EBIT indicates significant challenges in operational efficiency and profitability.

Balance Sheet

The balance sheet shows a relatively strong equity position with a Debt-to-Equity ratio of 0.19, indicating low leverage. The equity ratio stands at 68.8%, reflecting financial stability and a cushion against liabilities. However, the company has been consistently reporting net losses, impacting the return on equity negatively.

Cash Flow

Cyclopharm Limited's cash flow statement reveals ongoing challenges in generating positive cash flow, with a negative operating cash flow and free cash flow in 2024. The free cash flow growth rate and operating cash flow to net income ratio are concerning, indicating difficulties in sustaining operations through internal cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.79M	27.57M	26.34M	23.22M	17.70M	14.68M
Gross Profit	18.36M	17.93M	16.08M	5.94M	3.20M	2.08M
EBITDA	-14.93M	-13.69M	-3.84M	-6.47M	-5.79M	-7.73M
Net Income	-13.38M	-13.20M	-4.70M	-6.61M	-5.04M	-6.04M
Balance Sheet
Total Assets	55.91M	62.13M	45.91M	49.54M	55.74M	28.28M
Cash, Cash Equivalents and Short-Term Investments	12.41M	20.57M	11.73M	20.30M	29.25M	1.87M
Total Debt	7.98M	8.29M	4.23M	4.33M	4.51M	4.71M
Total Liabilities	19.81M	19.40M	13.65M	13.01M	12.67M	11.16M
Stockholders Equity	36.10M	42.73M	32.26M	36.54M	43.07M	17.12M
Cash Flow
Free Cash Flow	-14.36M	-13.55M	-7.74M	-8.21M	-2.79M	-9.47M
Operating Cash Flow	-13.71M	-12.57M	-7.20M	-6.66M	-1.63M	-8.93M
Investing Cash Flow	-804.71K	-971.86K	-508.47K	-1.55M	-1.16M	-874.19K
Financing Cash Flow	-967.63K	22.22M	-1.02M	-725.64K	30.17M	-985.96K

Cyclopharm Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYC, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.01, above the 50-day MA of 0.96, and above the 200-day MA of 0.95, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 54.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYC.

Cyclopharm Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARX	56 Neutral	AU$234.92M	-141.67	-2.01%	―	16.93%	76.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMP	48 Neutral	AU$74.91M	-54.35	-6.35%	―	2.23%	-263.16%
CYC	46 Neutral	AU$106.69M	-7.95	-31.98%	―	34.20%	-23.90%
IPD	45 Neutral	$42.81M	-1.83	-74.00%	―	23.31%	-17.35%
EMV	44 Neutral	AU$168.22M	-15.78	-70.55%	―	―	-257.32%
4DX	44 Neutral	AU$1.93B	-47.67	-44.49%	―	55.91%	22.60%

Cyclopharm Limited Corporate Events

Cyclopharm Backs AI-Enabled COPD Trial to Expand Reach of Technegas Lung Imaging

Cyclopharm has entered into a clinical research collaboration with Macquarie University and Macquarie University Hospital to support the Endoscopic Segmental Sealant Ablation (ESSA) Study, which will test a novel minimally invasive bronchoscopic procedure for patients with severe COPD who are not eligible for existing valve-based lung volume reduction therapies. The trial, led by Professor Alvin Ing, will use Technegas® functional lung imaging combined with AI-based analysis from Thirona on V/Q SPECT-CT scans to identify poorly functioning lung segments, guide targeted treatment with polymer foam, and quantitatively measure segment-level treatment response in 34 patients over about 12 months, positioning Cyclopharm’s technology at the centre of a next‑generation, personalised approach to COPD care and potentially expanding its addressable market in interventional respiratory medicine.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Technegas Named Preferred Ventilation Agent in Key US and Global Lung Imaging Guideline

Cyclopharm’s flagship lung imaging agent Technegas has been explicitly recognised as a preferred ventilation agent in a new draft ventilation–perfusion (V/Q) pulmonary scintigraphy guideline developed for leading US and international nuclear medicine societies. The draft, which marks the first major update to US-aligned lung imaging guidance since 2012, cites Technegas as generally preferred where available and highlights its role in enhancing diagnostic accuracy and expanding applications beyond pulmonary embolism to a range of respiratory and cardiothoracic indications, a move expected to accelerate US clinical demand, support broader institutional adoption and strengthen Technegas’ positioning in hospital procurement and reimbursement decisions.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.88 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Secures Insurer Indemnity in 4DMedical Legal Dispute

Cyclopharm Limited has confirmed that its insurer has accepted indemnity for legal proceedings brought against the company by 4DMedical Limited in the Supreme Court of Victoria and has taken over conduct of Cyclopharm’s defence. The insurer’s assumption of the defence is expected to mitigate potential financial and operational impacts on Cyclopharm as the case progresses, providing greater certainty for investors and other stakeholders while the company continues its focus on its core radiopharmaceutical operations and ongoing disclosure obligations.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.88 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Secures First U.S. Children’s Hospital Adoption of Technegas

Cyclopharm Limited has signed an agreement with Stanford Medicine Children’s Health for the implementation of its Technegas lung imaging technology at Lucile Packard Children’s Hospital Stanford, the first dedicated children’s hospital in the United States to adopt the product. The installation represents a key milestone in Cyclopharm’s early U.S. commercial rollout, underscoring Technegas’ appeal in paediatric care due to its low radiation dose, established safety profile, and suitability for high-quality functional lung imaging, and supports the company’s broader strategy to expand its presence across leading U.S. academic and clinical centres.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.97 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Wins Colombian Approval for Technegas, Extending Global Lung Imaging Footprint

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, lifting its global footprint to 67 countries and reinforcing its position in functional lung ventilation imaging. The move supports the company’s strategy to broaden access to low-radiation, high-resolution functional ventilation imaging that can be integrated with AI-enabled platforms for precise measurement of regional lung function. With Technegas now expanding into wider respiratory applications, including COPD, asthma, lung transplantation and oncologic planning, the Colombian approval is strategically timed ahead of the World Federation of Nuclear Medicine and Biology Congress in Cartagena in early 2026, providing a high-profile venue to showcase the technology and accelerate clinical adoption in partnership with local centres, which could further entrench Cyclopharm’s standing among nuclear medicine specialists globally.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.97 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Partners with Western University to Advance Asthma Detection

Cyclopharm Limited has partnered with Western University in Canada to explore the use of its Technegas® technology in detecting mild to moderate asthma in young adults. The clinical trial, led by Professor Grace Parraga, aims to determine if Technegas® can identify hidden lung ventilation issues in asthma patients, potentially changing clinical practices and expanding the use of Technegas® beyond its current applications. This research aligns with Cyclopharm’s strategy to broaden the clinical use of Technegas® and represents a significant growth opportunity for the company.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Sells Cyclotron Asset to Focus on Technegas® Expansion

Cyclopharm Limited has completed the sale of its non-core Cyclotron asset for $6.2 million, enhancing its balance sheet and aligning with its strategic focus on expanding the Technegas® business globally. The transaction provides financial flexibility to accelerate Technegas® commercial growth, and Cyclopharm continues to explore collaborative opportunities with Cyclotek to enhance patient access to advanced nuclear medicine solutions.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.